GFM
ADMA icon

GF Fund Management’s ADMA Biologics ADMA Stock Holding History

GF Fund Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.2K Buy
5,346
+670
+14% +$10.6K ﹤0.01% 403
2025
Q4 		$85.3K Sell
4,676
-458
-9% -$7.72K ﹤0.01% 362
2025
Q3 		$75.3K Sell
5,134
-919
-15% -$15.8K ﹤0.01% 357
2025
Q2 		$110K Hold
6,053
– – ﹤0.01% 357
2025
Q1 		$120K Buy
6,053
+1,089
+22% +$18.8K ﹤0.01% 352
2024
Q4 		$85.1K Buy
+4,964
New +$93.4K ﹤0.01% 339

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

GF Fund Management's ADMA Position: Q1 2026 in Review

GF Fund Management increased its ADMA Biologics (ADMA) stake by 14% in Q1 2026, buying an estimated $10.6K and bringing the position to 5,346 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #403.

GF Fund Management first reported a position in ADMA in Q4 2024 and has held it in 6 quarters since. The position peaked at $120K in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • GF Fund Management held 5,346 shares of ADMA Biologics worth $48.2K as of Q1 2026.
  • GF Fund Management bought 670 ADMA Biologics shares in Q1 2026, an estimated $10.6K.
  • ADMA Biologics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #403 holding.
  • GF Fund Management first reported a position in ADMA Biologics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's ADMA Biologics position peaked at $120K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.